Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro
about
Activity of gatifloxacin alone or in combination with pyrimethamine or gamma interferon against Toxoplasma gondiiHematopoietic pannexin 1 function is critical for neuropathic painTopoisomerase II inhibition involves characteristic chromosomal expression patterns.Activities of clinafloxacin, gatifloxacin, gemifloxacin, and trovafloxacin against recent clinical isolates of levofloxacin-resistant Streptococcus pneumoniae.Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance.Efficacy of trovafloxacin against penicillin-susceptible and multiresistant strains of Streptococcus pneumoniae in a mouse pneumonia model.ParC and GyrA may be interchangeable initial targets of some fluoroquinolones in Streptococcus pneumoniae.Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE lociIn vitro development of resistance to five quinolones and amoxicillin-clavulanate in Streptococcus pneumoniae.Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory seCloning and nucleotide sequence of the DNA gyrase (gyrA) gene from Mycoplasma hominis and characterization of quinolone-resistant mutants selected in vitro with trovafloxacin.Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae.Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.Evaluation of susceptibility testing to detect fluoroquinolone resistance mechanisms in Streptococcus pneumoniaeComparative in vitro activities of trovafloxacin (CP-99,219) against 445 gram-positive isolates from patients with endocarditis and those with other bloodstream infections.Characterization of a mutation in the parE gene that confers fluoroquinolone resistance in Streptococcus pneumoniaeThe new fluoroquinolones: A critical reviewTrovafloxacin-induced replication stress sensitizes HepG2 cells to tumor necrosis factor-alpha-induced cytotoxicity mediated by extracellular signal-regulated kinase and ataxia telangiectasia and Rad3-relatedEfficacy of trovafloxacin in treatment of experimental staphylococcal or streptococcal endocarditis.Primary targets of fluoroquinolones in Streptococcus pneumoniae.Streptococcus pneumoniae DNA gyrase and topoisomerase IV: overexpression, purification, and differential inhibition by fluoroquinolones.Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones.Activities of fluoroquinolones against Streptococcus pneumoniae type II topoisomerases purified as recombinant proteinsEngineering the specificity of antibacterial fluoroquinolones: benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target in Streptococcus pneumoniae from topoisomerase IV to gyrase.Horizontal transfer of parC and gyrA in fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae.In vitro selection of resistance to clinafloxacin, ciprofloxacin, and trovafloxacin in Streptococcus pneumoniae.In vitro development of resistance to six quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus.Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae.Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins.Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro.DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae.Grepafloxacin, a dimethyl derivative of ciprofloxacin, acts preferentially through gyrase in Streptococcus pneumoniae: role of the C-5 group in target specificity.Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones.Genetic characterization of fluoroquinolone-resistant Streptococcus pneumoniae strains isolated during ciprofloxacin therapy from a patient with bronchiectasisCefotaxime acts synergistically with levofloxacin in experimental meningitis due to penicillin-resistant pneumococci and prevents selection of levofloxacin-resistant mutants in vitro.Chemistry of polyhalogenated nitrobutadienes, 10: Synthesis of highly functionalized heterocycles with a rigid 6-amino-3-azabicyclo[3.1.0]hexane moiety.Preincubation of pneumococci with beta-lactams alone or combined with levofloxacin prevents quinolone-induced resistance without increasing intracellular levels of levofloxacin.Enantioselective palladium(0)-catalyzed intramolecular cyclopropane functionalization: access to dihydroquinolones, dihydroisoquinolones and the BMS-791325 ring system.Trovafloxacin attenuates neuroinflammation and improves outcome after traumatic brain injury in mice.
P2860
Q28345231-22DDE5B7-8D70-4F27-B2AA-775AD6912676Q30274778-A6044CBF-9B60-406F-AC9D-078F817672E2Q33350077-00CCC691-8203-4A01-88F1-BCE2630D3AD4Q33593776-C6CF354B-A56E-4A57-B0A0-A6D012FD3A2EQ33594174-52E5C4EC-529D-47C6-BDE7-976ECBDEB8E6Q33692694-98D3B146-C1E0-452F-AC10-192DF2704BF4Q33976037-FF8AE6E5-8ADF-458E-B9D5-DCBB9F5D3310Q33976055-51A6E92F-F4C5-47AB-8B32-27827DB74C23Q33976279-35FDC56C-0788-43CF-BAED-C4E728B67221Q33978849-DA88C0D3-02EA-4422-9A25-5E8C5CAA6B45Q33980747-8407AAC4-A873-41BC-84EA-8552A1D8DA8FQ33981343-13888380-D690-44B6-BB98-EFC01CB2970BQ33982211-77784D62-749A-4060-80B2-2BB4F4B1A1E3Q33982417-D4DD088A-EB14-4117-9866-1D772476002CQ35136236-EA12705A-439E-40AE-82D9-34FFED945802Q35136293-D7C0DB1F-A563-4C4E-AC3D-2D0E96ED3D52Q35649595-9F32497D-32C7-42F2-99F8-E699B4778DF1Q35651970-56E9FE1B-ADCC-4A54-876A-6D3BD89BB4DEQ39469535-ED612C36-36EB-439F-93CF-72C2EE94EB71Q39469902-82002B1F-5EF4-4AE6-B5FC-8A7F73B3F5E4Q39470064-8910708D-0B06-415C-8199-A2118ACC3D3EQ39471404-D6B84496-84DA-4C6B-A582-785D9722E285Q39471518-1ED43039-90E4-4974-AE04-12C80C27D2D6Q39472105-0773BFA1-AA9D-4581-B87B-EC6195E7AD89Q39472798-7DDF4E4F-C2B5-4FB9-A418-5D2FB5C6EA14Q39473366-1483A7A8-D62C-4654-A0D4-EC940913DA0DQ39475328-73725A9B-286B-4F8F-9F56-E26C746A4C74Q39476686-0E252BDF-069D-45F3-991D-2DE790AF7060Q39477371-6E2B56F7-3F84-48AA-99BB-F2D51AE61BEEQ39478835-E7890C8F-4F1D-4C6E-9C27-79918DA63071Q39537237-C1BEBA3D-72A7-4950-9CC8-A2B2D2C9E487Q39559340-1F45D5D8-0A15-4FCB-A14B-EF902B4FF165Q39651301-84A7E885-C52A-4F76-ADBB-2637AAA65458Q39651324-520F10E5-5CB8-4E8E-B252-0748A02ACAA1Q39743472-464B547E-DF21-4B72-9CDA-002155A0CDDFQ39792641-D3D61CFA-F1C2-42A1-9E61-95225088398CQ42146031-A63573F6-1015-436C-BD56-1C5286C01265Q42949270-A58858FB-9467-49FD-9439-EE646DC20238Q47137062-35DF85A9-8233-4D97-8E1F-16096FA7401FQ50032496-F921292C-BAAC-4F73-AC96-E3D5E8062CB8
P2860
Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro
description
1996 nî lūn-bûn
@nan
1996 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Activity of the new fluoroquin ...... s pneumoniae selected in vitro
@ast
Activity of the new fluoroquin ...... s pneumoniae selected in vitro
@en
Activity of the new fluoroquin ...... s pneumoniae selected in vitro
@nl
type
label
Activity of the new fluoroquin ...... s pneumoniae selected in vitro
@ast
Activity of the new fluoroquin ...... s pneumoniae selected in vitro
@en
Activity of the new fluoroquin ...... s pneumoniae selected in vitro
@nl
prefLabel
Activity of the new fluoroquin ...... s pneumoniae selected in vitro
@ast
Activity of the new fluoroquin ...... s pneumoniae selected in vitro
@en
Activity of the new fluoroquin ...... s pneumoniae selected in vitro
@nl
P2093
P2860
P1476
Activity of the new fluoroquin ...... s pneumoniae selected in vitro
@en
P2093
B Schmieder
J Tankovic
P Courvalin
R J Polzer
R Zaniewski
P2860
P304
P407
P577
1996-12-01T00:00:00Z